Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Discover the results of two recent clinical studies of IVIg treatments for CIDP.
Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Discover the results of two recent clinical studies of IVIg treatments for CIDP.
Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.